First Hawaiian Bank Innoviva, Inc. Transaction History

First Hawaiian Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 12, 2021	SELL	$9.33 - $12.48 $248,551 - $332,467	-26,640 Closed	0 $0
Q2 2019 Jul 15, 2019	SELL	$13.1 - $14.95 $54,941 - $62,700	-4,194 Reduced 13.6%	26,640 $388,000
Q1 2019 Apr 02, 2019	BUY	$13.69 - $20.06 $41,398 - $60,661	3,024 Added 10.87%	30,834 $433,000
Q4 2018 Jan 11, 2019	BUY	$13.96 - $18.26 $69 - $91	5 Added 0.02%	27,810 $485,000
Q3 2018 Oct 16, 2018	BUY	$13.63 - $15.7 $378,982 - $436,538	27,805 New	27,805 $424,000

240

77M

53.9K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.26B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

Stay updated on First Hawaiian Bank with notifications on news.